Such agents can therefore, (i) lower drug elimination to increase systemic circulation time, (ii) lower maximum plasma concentration (Cmax) to reduce drug side effects, (iii) enhance tumor tissue uptake and exposure to the anti-cancer drug; these principles can in turn yield an improved therapeutic index for cancer therapy. Several Inhibitors,research,lifescience,medical ITF2357 liposomal formulated cancer

drugs have been evaluated in various cancers, but only a limited number have been applied to pancreatic cancer. Liposomal Doxorubicin The first liposomal anti-cancer drug approved by the Food and Drug Administration (FDA) was pegylated liposomal doxorubicin (Caelyx®/Doxil®) in 1995 for Karposi’s sarcoma (16)-(18). It has been subsequently approved for the treatment of multiple myeloma and recurrent epithelial Inhibitors,research,lifescience,medical ovarian cancer as well. It also has been evaluated for the treatment of pancreatic cancer in animal xenograft model and in clinical trials. In a preclinical study, Vagge et al showed that pegylated liposomal doxorubicin was significantly more effective in inhibiting the growth of human Inhibitors,research,lifescience,medical pancreatic

cancer xenograft in nude mice as compared to free form doxorubicin (19). Using confocal laser scanning microscopy and microfluorimetry to quantitate the uptake of intravenously injected doxorubicin in tumor tissue, the authors found that the content of doxorubicin in tumor site of animal receiving liposomal formulated drug was 6 folds or Inhibitors,research,lifescience,medical higher compared to free doxorubicin. Based on the results, Halford et al conducted a phase II trial to evaluate

the therapeutic efficacy of Caelyx® in 22 chemo-naïve patients with unresectable pancreatic carcinoma. The dose was escalated from 30 mg/m2 (in the first two patients) Inhibitors,research,lifescience,medical to 50 mg/m(2) intravenous injection every 3 weeks (20). Of the 20 patients received the treatment, the most common grade 3 toxicity were stomatitis (20%) and nausea (10%), the best tumor response was stable diseases in 6 (30%), and the median overall survival was 3.2 months with one year survival rate of 10%. These finding excluded the use of Caelyx® monotherapy in the treatment of advanced pancreatic cancer. The combination of Caelyx® with infusional 5-FU/leucovorin and mitomycin-C has been 3-mercaptopyruvate sulfurtransferase evaluated in a phase I trial in patients with upper gastrointestinal cancer. In that study, escalating dose of Caelyx® (15 – 35 mg/m2) day 1 and 29 in combination with weekly 24-hour infusion of 5-FU and leucovorin (2,000 and 500 mg/m2, respectively) for 6 weeks, and mitomycin-C 7 mg/m2 day 8 and 36, every 8 weeks as one cycle. The most common grade 3-4 toxicities were nausea/vomiting (29%), diarrhea (18%) and leucopenia (12%). Of the 14 accruals with pre-treated pancreatic cancer, the best tumor response was partial response in one and minor response in 2, and the overall survival after the study treatment was 6.5 months (21).